secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001737287-24-000075
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual
--------------------------------------------------------------------------------

- Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.
- Enrollment slower than anticipated due to emergence of new alternative treatment options.
- Interest among investigators remains high but company is reallocating resources to other pipeline programs.
- No financial impact or guidance changes disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000075/0001737287-24-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000075/allo-20241111.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer